GC Biopharma's recombinant anthrax vaccine 'BARYTHRAX', developed in Korea, has successfully demonstrated safety and immunogenicity in Phase 2 clinical trials, with the research findings published in the international academic journal 'Vaccine'. This study, disclosed via BioSpace on November 3rd, was a randomized, double-blind, placebo-controlled Phase 2 clinical trial conducted with the approval of the Korean Ministry of Food and Drug Safety (MFDS). BARYTHRAX is a vaccine that produces the Protective Antigen (PA) protein of Bacillus anthracis using genetic recombination technology. Unlike existing cell culture-based or animal-derived vaccines, it allows for safer and more efficient production. Anthrax is a fatal infectious disease that can be exploited as a biological weapon, and the importance of vaccine development has been further highlighted since the 2001 anthrax letter attacks in the United States. GC Biopharma's BARYTHRAX marks a significant milestone in strengthening Korea's national biodefense capabilities as the first recombinant anthrax vaccine developed with indigenous technology. The Phase 2 clinical data confirmed that BARYTHRAX induces a high immune response while exhibiting an excellent safety profile. Participants effectively generated protective antibodies against Bacillus anthracis after vaccination with BARYTHRAX, providing immunity that can prevent anthrax or alleviate symptoms in the event of actual infection. The double-blind, placebo-controlled design is a rigorous methodology for objectively evaluating vaccine efficacy, conducted without participants or researchers knowing who received the actual vaccine. This minimized bias and secured reliable data. Based on these Phase 2 results, GC Biopharma aims for additional Phase 3 clinical trials and global regulatory approvals. Recombinant protein technology is superior in terms of production speed and scalability, offering the advantage of rapid response in public health crises requiring mass production. The success of BARYTHRAX serves as an opportunity for the Korean biopharmaceutical industry to secure vaccine sovereignty and prove its competitiveness in the global biodefense market. Amid the renewed strategic importance of vaccines highlighted by the COVID-19 pandemic, countries are making all-out efforts to secure their own vaccine development capabilities. GC Biopharma, already a globally competitive company in blood products and biosimilars, is expanding its vaccine portfolio with BARYTHRAX, evolving into a comprehensive biopharmaceutical company. Demand for anthrax vaccines is anticipated for various uses, including military purposes, preparedness for bioterrorism, and protection of laboratory workers, with significant demand for stockpiles from global health authorities, including the U.S. CDC (Centers for Disease Control and Prevention). If GC Biopharma obtains approval from the FDA and European EMA in the future, it is expected to establish itself as a key supplier in the global biodefense vaccine market.